FIRSTREGULARSESSION
HOUSEBILLNO.1367
103RDGENERALASSEMBLY
INTRODUCEDBYREPRESENTATIVESELF.
2770H.01I JOSEPHENGLER,ChiefClerk
ANACT
Torepealsection195.017,RSMo,andtoenactinlieuthereoftwonewsectionsrelatingto
abortifacientdrugs,withapenaltyprovision.
BeitenactedbytheGeneralAssemblyofthestateofMissouri,asfollows:
SectionA.Section195.017,RSMo,isrepealedandtwonewsectionsenactedinlieu
2thereof,tobeknownassections195.017and579.018,toreadasfollows:
195.017.1.Thedepartmentofhealthandseniorservicesshallplaceasubstancein
2ScheduleIifitfindsthatthesubstance:
3 (1)Hashighpotentialforabuse;and
4 (2)HasnoacceptedmedicaluseintreatmentintheUnitedStatesorlacksaccepted
5safetyforuseintreatmentundermedicalsupervision.
6 2.ScheduleI:
7 (1)ThecontrolledsubstanceslistedinthissubsectionareincludedinScheduleI;
8 (2)Anyofthefollowingopiates,includingtheirisomers,esters,ethers,salts,and
9saltsofisomers,esters,andethers,unlessspecificallyexcepted,whenevertheexistenceof
10theseisomers,esters,ethersandsaltsispossiblewithinthespecificchemicaldesignation:
11 (a)Acetyl-alpha-methylfentanyl(N-(1-(1-methyl-2-phenethyl)-4-piperidinyl)-N-
12phenylacetamide);
13 (b)Acetylmethadol;
14 (c)Acetylfentanyl(N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
15 (d)Acrylfentanyl(-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide);
16 (e)AH-7921(3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide);
17 (f)Allylprodine;
EXPLANATION—Matterenclosedinbold-facedbrackets[thus] intheabovebillisnotenactedandis
intendedtobeomittedfromthelaw.Matterinbold-facetypeintheabovebillisproposedlanguage. 18 (g)Alphacetylmethadol(exceptlevoalphacetylmethadol,alsoknownaslevo-alpha-
19acetylmethadollevothadylacetateorLAAM);
20 (h)Alphameprodine;
21 (i)Alphamethadol;
22 (j)Alpha-methylfentanyl(N-1-(alphamethyl-beta-phenyl)ethyl-4-piperidyl)
23propionanilide;1-(1-methyl-2-phenylethyl)-4((N-propanilido)piperidine);
24 (k)Alpha-methylthiofentanyl(N-(1-methyl-2-(2-thienyl)ethyl-4-piperidinyl)-N-
25phenylpropanamide);
26 (l)Benzethidine;
27 (m)Betacetylmethadol;
28 (n)Beta-hydroxyfentanyl(N-(1-(2-hydroxy-2-phenethyl)-4-piperidinyl)-N-
29phenylpropanamide);
30 (o)Beta-hydroxy-3-methylfentanyl(N-(1-(2-hydroxy-2-phenethyl)-3-methyl-4-
31piperidinyl)-N-phenylpropanamide);
32 (p)Betameprodine;
33 (q)Betamethadol;
34 (r)Betaprodine;
35 (s)Clonitazene;
36 (t)Dextromoramide;
37 (u)Diampromide;
38 (v)Cyclopropylfentanyl;
39 (w)Diethylthiambutene;
40 (x)Difenoxin;
41 (y)Dimenoxadol;
42 (z)Dimepheptanol;
43 (aa)Dimethylthiambutene;
44 (bb)Dioxaphetylbutyrate;
45 (cc)Dipipanone;
46 (dd)Ethylmethylthiambutene;
47 (ee)Etonitazene;
48 (ff)Etoxeridine;
49 (gg)4-fluoroisobutyrylfentanyl-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)
50isobutyramide;
51 (hh)Furanylfentanyl-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide;
52 (ii)Furethidine;
53 (jj)Hydroxypethidine;
54 (kk)Ketobemidone;
HB1367 2 55 (ll)Levomoramide;
56 (mm)Levophenacylmorphan;
57 (nn)3-Methylfentanyl(N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-
58phenylproanamide),itsopticalandgeometricisomers,salts,andsaltsofisomers;
59 (oo)3-Methylthiofentanyl(N-((3-methyl-1-(2-thienyl)ethyl-4-piperidinyl)-N-
60phenylpropanamide);
61 (pp)Methoxyacetylfentanyl(2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-
62phenylacetamide);
63 (qq)Morpheridine;
64 (rr)MPPP(1-methyl-4-phenyl-4-propionoxypiperidine);
65 (ss)MT-45(1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);
66 (tt)Noracymethadol;
67 (uu)Norlevorphanol;
68 (vv)Normethadone;
69 (ww)Norpipanone;
70 (xx)OcfentanilN-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)
71acetamide;
72 (yy)Ortho-fluorofentanyl(N-2-(1-phenethylpiperidin-yl)propionamide);othername
732-fluorofentanyl;
74 (zz)para-fluorobutyrylfentanyl(N-4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)
75butyramide;
76 (aaa)Para-fluorofentanyl(N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-piperidinyl)
77propanamide;
78 (bbb)PEPAP(1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
79 (ccc)Phenadoxone;
80 (ddd)Phenampromide;
81 (eee)Phenomorphan;
82 (fff)Phenoperidine;
83 (ggg)Piritramide;
84 (hhh)Proheptazine;
85 (iii)Properidine;
86 (jjj)Propiram;
87 (kkk)Racemoramide;
88 (lll)Tetrahydrofuranylfentanyl(N-(1-phenethylpiperidin-4-yl)-N-
89phenyltetrahydrofuran-2-carboxamide);
90 (mmm)Thiofentanyl(-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-propanamide;
91 (nnn)Tilidine;
HB1367 3 92 (ooo)Trimeperidine;
93 (3)Anyofthefollowingopiumderivatives,theirsalts,isomersandsaltsofisomers
94unlessspecificallyexcepted,whenevertheexistenceofthesesalts,isomersandsaltsof
95isomersispossiblewithinthespecificchemicaldesignation:
96 (a)Acetorphine;
97 (b)Acetyldihydrocodeine;
98 (c)Benzylmorphine;
99 (d)Codeinemethylbromide;
100 (e)Codeine-N-Oxide;
101 (f)Cyprenorphine;
102 (g)Desomorphine;
103 (h)Dihydromorphine;
104 (i)Drotebanol;
105 (j)Etorphine(excepthydrochloridesalt);
106 (k)Heroin;
107 (l)Hydromorphinol;
108 (m)Methyldesorphine;
109 (n)Methyldihydromorphine;
110 (o)Morphinemethylbromide;
111 (p)Morphinemethylsulfonate;
112 (q)Morphine-N-Oxide;
113 (r)Myrophine;
114 (s)Nicocodeine;
115 (t)Nicomorphine;
116 (u)Normorphine;
117 (v)Pholcodine;
118 (w)Thebacon;
119 (4)AnyofthefollowingopiatesimilarsyntheticsubstancesscheduledbytheU.S.
120DrugEnforcementAdministrationassubstancesthatshareapharmacologicalprofilesimilar
121tofentanyl,morphine,andothersyntheticopioids,unlessspecificallyexceptedorunless
122listedinanotherschedule:
123 (a)Butyrylfentanyl(N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide);
124 (b)U-47700(3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]–methylbenzamide).
125 (5)Anymaterial,compound,mixtureorpreparationwhichcontainsanyquantityof
126thefollowinghallucinogenicsubstances,theirsalts,isomersandsaltsofisomers,unless
127specificallyexcepted,whenevertheexistenceofthesesalts,isomers,andsaltsofisomersis
128possiblewithinthespecificchemicaldesignation:
HB1367 4 129 (a)Alpha-ethyltryptamine;
130 (b)4-bromo-2,5-dimethoxyamphetamine;
131 (c)4-bromo-2,5-dimethoxyphenethylamine;
132 (d)2,5-dimethoxyamphetamine;
133 (e)2,5-dimethoxy-4-ethylamphetamine;
134 (f)2,5-dimethoxy-4-(n)-propylthiophenethylamine;
135 (g)2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine;
136 (h)2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine;
137 (i)2-(2,5-Dimethoxy-4-methylphenyl)ethanamine;
138 (j)2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine;
139 (k)2-(2,5-Dimethoxyphenyl)ethanamine;
140 (l)2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine;
141 (m)2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine;
142 (n)2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine;
143 (o)2-(4-Isopropylthio)-2,5-dimethoxyphenyl)ethanamine;
144 (p)4-methoxyamphetamine;
145 (q)5-methoxy-3,4-methylenedioxyamphetamine;
146 (r)4-methyl-2,5-dimethoxyamphetamine;
147 (s)3,4-methylenedioxyamphetamine;
148 (t)3,4-methylenedioxymethamphetamine;
149 (u)3,4-methylenedioxy-N-ethylamphetamine;
150 (v)N-hydroxy-3,4-methylenedioxyamphetamine;
151 (w)3,4,5-trimethoxyamphetamine;
152 (x)5-MeO-DMTor5-methoxy-N,N-dimethyltryptamine;
153 (y)Alpha-methyltryptamine;
154 (z)Bufotenine;
155 (aa)Diethyltryptamine;
156 (bb)Dimethyltryptamine;
157 (cc)5-methoxy-N,N-diisopropyltryptamine;
158 (dd)Ibogaine;
159 (ee)Lysergicaciddiethylamide;
160 (ff)Marijuanaormarihuana,exceptindustrialhemp;
161 (gg)Mescaline;
162 (hh)Parahexyl;
163 (ii)Peyote,toincludeallpartsoftheplantpresentlyclassifiedbotanicallyas
164LophophorawilliamsiiLemaire,whethergrowingornot;theseedsthereof;anyextractfrom
HB1367 5 165anypartofsuchplant;andeverycompound,manufacture,salt,derivative,mixtureor
166preparationoftheplant,itsseedorextracts;
167 (jj)N-ethyl-3-piperidylbenzilate;
168 (kk)N-methyl-3-piperidylbenzilate;
169 (ll)Psilocybin;
170 (mm)Psilocyn;
171 (nn)TetrahydrocannabinolsnaturallycontainedinaplantofthegenusCannabis
172(cannabisplant),exceptindustrialhemp,aswellassyntheticequivalentsofthesubstances
173containedinthecannabisplant,orintheresinousextractivesofsuchplant,orsynthetic
174substances,derivativesandtheirisomers,orboth,withsimilarchemicalstructureand
175pharmacologicalactivitytothosesubstancescontainedintheplant,suchasthefollowing:
176 a.1cisortranstetrahydrocannabinolandtheiropticalisomers;
177 b.6cisortranstetrahydrocannabinolandtheiropticalisomers;
178 c.3,4cisortranstetrahydrocannabinolandtheiropticalisomers;
179 d.Anycompoundsofthesestructures,regardlessofnumericaldesignationofatomic
180positionscovered;
181 (oo)Ethylamineanalogofphencyclidine;
182 (pp)Pyrrolidineanalogofphencyclidine;
183 (qq)Thiopheneanalogofphencyclidine;
184 (rr)1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
185 (ss)Salviadivinorum;
186 (tt)SalvinorinA;
187 (uu)Syntheticcannabinoids:
188 a.Anycompoundstructurallyderivedfrom3-(1-naphthoyl)indoleor1H-indol-3-yl-
189(1-naphthyl)methanebysubstitutionatthenitrogenatomoftheindoleringbyalkyl,
190haloalkyl,alkenyl,cycloalkylmethyl,cycloalkylethyl,1-(N-methyl-2-piperidinyl)methylor2-
191(4-morpholinyl)ethylgroup,whetherornotfurthersubstitutedintheindoleringtoanyextent,
192whetherornotsubstitutedinthenaphthylringtoanyextent.Including,butnotlimitedto:
193 (i)AM2201,or1-(5-fluoropentyl)-3-(1-naphthoyl)indole;
194 (ii)JWH-007,or1-pentyl-2-methyl-3-(1-naphthoyl)indole;
195 (iii)JWH-015,or1-propyl-2-methyl-3-(1-naphthoyl)indole;
196 (iv)JWH-018,or1-pentyl-3-(1-naphthoyl)indole;
197 (v)JWH-019,or1-hexyl-3-(1-naphthoyl)indole;
198 (vi)JWH-073,or1-butyl-3-(1-naphthoyl)indole;
199 (vii)JWH-081,or1-pentyl-3-(4-methoxy-1-naphthoyl)indole;
200 (viii)JWH-098,or1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole;
201 (ix)JWH-122,or1-pentyl-3-(4-methyl-1-naphthoyl)indole;
HB1367 6 202 (x)JWH-164,or1-pentyl-3-(7-methoxy-1-naphthoyl)indole;
203 (xi)JWH-200,or1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
204 (xii)JWH-210,or1-pentyl-3-(4-ethyl-1-naphthoyl)indole;
205 (xiii)JWH-398,or1-pentyl-3-(4-chloro-1-naphthoyl)indole;
206 b.Anycompoundstructurallyderivedfrom3-(1-naphthoyl)pyrrolebysubstitutionat
207thenitrogenatomofthepyrroleringbyalkyl,haloalkyl,alkenyl,cycloalkylmethyl,
208cycloalkylethyl,1-(N-methyl-2-piperidinyl)methylor2-(4-morpholinyl)ethylgroup,whether
209ornotfurthersubstitutedinthepyrroleringtoanyextent,whetherornotsubstitutedinthe
210naphthylringtoanyextent;
211 c.Anycompoundstructurallyderivedfrom1-(1-naphthylmethyl)indeneby
212substitutionatthe3-positionoftheindeneringbyalkyl,haloalkyl,alkenyl,
213cycloalkylmethyl,cycloalkylethyl,1-(N-methyl-2-piperidinyl)methylor2-(4-morpholinyl)
214ethylgroup,whetherornotfurthersubstitutedintheindeneringtoanyextent,whetherornot
215substitutedinthenaphthylringtoanyextent;
216 d.Anycompoundstructurallyderivedfrom3-phenylacetylindolebysubstitutionat
217thenitrogenatomoftheindoleringwithalkyl,haloalkyl,alkenyl,cycloalkylmethyl,
218cycloalkylethyl,1-(N-methyl-2-piperidinyl)methylor2-(4-morpholinyl)ethylgroup,whether
219ornotfurthersubstitutedintheindoleringtoanyextent,whetherornotsubstitutedinthe
220phenylringtoanyextent.Including,butnotlimitedto:
221 (i)JWH-201,or1-pentyl-3-(4-methoxyphenylacetyl)indole;
222 (ii)JWH-203,or1-pentyl-3-(2-chlorophenylacetyl)indole;
223 (iii)JWH-250,or1-pentyl-3-(2-methoxyphenylacetyl)indole;
224 (iv)JWH-251,or1-pentyl-3-(2-methylphenylacetyl)indole;
225 (v)RCS-8,or1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole;
226 e.Anycompoundstructurallyderivedfrom2-(3-hydroxycyclohexyl)phenolby
227substitutionatthe5-positionofthephenolicringbyalkyl,haloalkyl,alkenyl,
228cycloalkylmethyl,cycloalkylethyl,1-(N-methyl-2-piperidinyl)methylor2-(4-morpholinyl)
229ethylgroup,whetherornotsubstitutedinthecyclohexylringtoanyextent.Including,but
230notlimitedtoCP47,497andhomologues,or2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-
231methyloctan-2-yl)phenol,wheresidechainn=5,andhomologueswheresidechainn-4,6,or
2327;
233 f.Anycompoundcontaininga3-(benzoyl)indolestructurewithsubstitutionatthe
234nitrogenatomoftheindoleringbyalkyl,haloalkyl,alkenyl,cycloalkylmethyl,
235cycloalkylethyl,1-(N-methyl-2-piperidinyl)methylor2-(4-morpholinyl)ethylgroup,
236whetherornotfurthersubstitutedintheindoleringtoanyextentandwhetherornot
237substitutedinthephenylringtoanyextent.Including,butnotlimitedto:
238 (i)AM-694,or1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;
HB1367 7 239 (ii)RCS-4,or1-pentyl-3-(4-methoxybenzoyl)indole(SR-19andRCS-4);
240 g.CP50,556-1,or[(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-
2412-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate;
242 h.HU-210,or(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-
2436a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
244 i.HU-211,orDexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
245methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
246 j.Dimethylheptylpyran,orDMHP;
247 (6)Anymaterial,compound,mixtureorpreparationcontaininganyquantityofthe
248followingsubstanceshavingadepressanteffectonthecentralnervoussystem,includingtheir
249salts,isomersandsaltsofisomerswhenevertheexistenceofthesesalts,isomersandsaltsof
250isomersispossiblewithinthespecificchemicaldesignation:
251 (a)Gamma-hydroxybutyricacid;
252 (b)Mecloqualone;
253 (c)Methaqualone;
254 (7)Anymaterial,compound,mixtureorpreparationcontaininganyquantityofthe
255followingsubstanceshavingastimulanteffectonthecentralnervoussystem,includingtheir
256salts,isomersandsaltsofisomers:
257 (a)Aminorex;
258 (b)N-benzylpiperazine;
259 (c)Cathinone;
260 (d)Fenethylline;
261 (e)3-Fluoromethcathinone;
262 (f)4-Fluoromethcathinone;
263 (g)Mephedrone,or4-methylmethcathinone;
264 (h)Methcathinone;
265 (i)4-methoxymethcathinone;
266 (j)(+,-)cis-4-methylaminorex((+,-)cis-4,5-dihydro-4-methyl-5-phenyl-2-
267oxazolamine);
268 (k)Methylenedioxypyrovalerone,MDPV,or1-(1,3-Benzodioxol-5-yl)-2-(1-
269pyrrolidinyl)-1-pentanone;
270 (l)Methylone,or3,4-Methylenedioxymethcathinone;
271 (m)4-Methyl-alpha-pyrrolidinobutiophenone,orMPBP;
272 (n)N-ethylamphetamine;
273 (o)N,N-dimethylamphetamine;
274 (p)Quinolin-8-yl1-pentyl-1H-indole-3-carboxylate(PB-22;QUPIC);
HB1367 8 275 (q)Quinolin-8-yl1-(5-fluoropentyl)-1H-indole-3-carboxylate(5-fluoro-PB-22;5F-
276PB-22);
277 (r)N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
278carboxamide(AB-FUBINACA);
279 (s)N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide
280(ADB-PINACA);
281 (8)Atemporarylistingofsubstancessubjecttoemergencyschedulingunderfederal
282lawshallincludeanymaterial,compound,mixtureorpreparationwhichcontainsany
283quantityofthefollowingsubstances:
284 (a)(1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone,itsoptical,
285positional,andgeometricisomers,salts,andsaltsofisomers;
286 (b)[1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone,
287itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers;
288 (c)N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,itsoptical,positional,and
289geometricisomers,salts,andsaltsofisomers;
290 (d)2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine,itsoptical,
291positional,andgeometricisomers,salts,andsaltsofisomers;
292 (e)2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine,itsoptical,
293positional,andgeometricisomers,salts,andsaltsofisomers;
294 (f)2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine,itsoptical,
295positional,andgeometricisomers,salts,andsaltsofisomers;
296 (g)4-methyl-N-ethylcathinone,itsoptical,positional,andgeometricisomers,salts,
297andsaltsofisomers;
298 (h)4-methyl-alpha-pyrrolidinopropiophenone,itsoptical,positional,andgeometric
299isomers,salts,andsaltsofisomers;
300 (i)Alpha-pyrrolidinopentiophenone,itsoptical,positional,andgeometricisomers,
301salts,andsaltsofisomers;
302 (j)Butylone,itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers;
303 (k)Pentedrone,itsoptical,positional,andgeometricisomers,salts,andsaltsof
304isomers;
305 (l)Pentylone,itsoptical,positional,andgeometricisomers,salts,andsaltsof
306isomers;
307 (m)Naphyrone,itsoptical,positional,andgeometricisomers,salts,andsaltsof
308isomers;
309 (n)Alpha-pyrrolidinobutiophenone,itsoptical,positional,andgeometricisomers,
310salts,andsaltsofisomers;
HB1367 9 311 (o)N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-
312carboxamide,itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers;
313 (p)N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide,its
314optical,positional,andgeometricisomers,salts,andsaltsofisomers;
315 (q)[1-(5-fluoropentyl)-1H-indazole-3-yl](naphthalen-1-yl)methanone,itsoptical,
316positional,andgeometricisomers,salts,andsaltsofisomers;
317 (r)N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide,
318itsisomers,esters,ethers,salts,andsaltsofisomers,esters,andethers;
319 (s)N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide,itsoptical,positional,and
320geometricisomers,salts,andsaltsofisomers;
321 (t)N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-
322carboxamide,itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers;
323 (u)methyl2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-
324dimethylbutanoate,itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers;
325 (v)methyl2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate,its
326optical,positional,andgeometricisomers,salts,andsaltsofisomers;
327 (w)N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide,itsoptical,
328positional,andgeometricisomers,salts,andsaltsofisomers;
329 (x)N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
330carboxamide,itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers;
331 (y)methyl2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-
332dimethylbutanoate,itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers;
333 (z)methyl2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-
334dimethylbutanoate,itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers;
335 (aa)N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide,itsisomers,
336esters,ethers,salts,andsaltsofisomers,esters,andethers;
337 (bb)methyl2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate,
338itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers;
339 (cc)N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide,itsisomers,
340esters,ethers,salts,andsaltsofisomers,esters,andethers;
341 (dd)N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide,itsisomers,esters,ethers,
342salts,andsaltsofisomers,esters,andethers;
343 (ee)N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide,itsisomers,esters,
344ethers,salts,andsaltsofisomers,esters,andethers;
345 (ff)N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide,itsisomers,
346esters,ethers,salts,andsaltsofisomers,esters,andethers;
HB1367 10 347 (gg)N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide,itsisomers,
348esters,ethers,salts,andsaltsofisomers,esters,andethers;
349 (hh)N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide,itsisomers,esters,
350ethers,salts,andsaltsofisomers,esters,andethers;
351 (ii)N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide,itsisomers,
352esters,ethers,salts,andsaltsofisomers,esters,andethers;
353 (jj)Fentanyl-relatedsubstances,theirisomers,esters,ethers,salts,andsaltsof
354isomers,esters,andethers.Fentanyl-relatedsubstanceshallmeananysubstancenot
355otherwiselistedunderanotherDrugEnforcementAdministrationControlledSubstanceCode
356Number,andforwhichnoexemptionorapprovalisineffectundersection505oftheFederal
357Food,Drug,andCosmeticAct,21U.S.C.Section355,thatisstructurallyrelatedtofentanyl
358byoneormoreofthefollowingmodifications:
359 a.Replacementofthephenylportionofthephenethylgroupbyanymonocycle,
360whetherornotfurthersubstitutedinoronthemonocycle;
361 b.Substitutioninoronthephenethylgroupwithalkyl,alkenyl,alkoxyl,hydroxyl,
362halo,haloalkyl,aminoornitrogroups;
363 c.Substitutioninoronthepiperidineringwithalkyl,alkenyl,alkoxyl,ester,ether,
364hydroxyl,aminoornitrogroups;
365 d.Replacementoftheanilineringwithanyaromaticmonocycle,whetherornot
366furthersubstitutedinoronthearomaticmonocycle;or
367 e.ReplacementoftheN-propionylgroupbyanotheracylgroup;
368 (kk)Naphthalen-1-yl1-(5-fluoropentyl)-1H-indole-3-carboxylate,itsoptical,
369positional,andgeometricisomers,salts,andsaltsofisomers(NM2201;CBL2201);
370 (ll)N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-
371carboxamide,itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers(5F-
372AB-PINACA);
373 (mm)1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide,its
374optical,positional,andgeometricisomers,salts,andsaltsofisomers(4-CN-CUMYL-
375BUTINACA;4-cyano-CUMYL-BUTINACA; 4-CN-CUMYLBINACA; CUMYL-4CN-
376BINACA;SGT-78);
377 (nn)methyl2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate,
378itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers(MMB-CHMICA,
379AMB-CHMICA);
380 (oo)1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-
381carboxamide,itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers(5F-
382CUMYL-P7AICA);
HB1367 11 383 (pp)N-ethylpentylone,itsoptical,positional,andgeometricisomers,salts,andsalts
384ofisomers(ephylone,1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one;
385 (qq)ethyl2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate,
386itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers(trivialname:5F-
387EDMB-PINACA);
388 (rr)methyl2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate,
389itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers(trivialname:5F-
390MDMB-PICA);
391 (ss)N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide,itsoptical,
392positional,andgeometricisomers,salts,andsaltsofisomers(trivialnames:FUB-AKB48;
393FUB-APINACA;AKB48N-(4-FLUOROBENZYL));
394 (tt)1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide,its
395optical,positional,andgeometricisomers,salts,andsaltsofisomers(trivialnames:5F-
396CUMYL-PINACA;SGT-25);
397 (uu)(1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone,
398itsoptical,positional,andgeometricisomers,salts,andsaltsofisomers(trivialname:FUB-
399144);
400 (vv)N-ethylhexedrone,itsoptical,positional,andgeometricisomers,salts,andsalts
401ofisomers(Othername:2-(ethylamino)-1-phenylhexan-1-one);
402 (ww)alpha-pyrrolidinohexanophenone,itsoptical,positional,andgeometricisomers,
403salts,andsaltsofisomers(Othernames:α-PHP;alpha-pyrrolidinohexiophenone;1-phenyl-2-
404(pyrrolidin-1-yl)hexan-1-one);
405 (xx)4-methyl-alpha-ethylaminopentiophenone,itsoptical,positional,andgeometric
406isomers,salts,andsaltsofisomers;(Othernames:4-MEAP;2-(ethylamino)-1-(4-
407methylphenyl)pentan-1-one);
408 (yy)4'-methyl-alpha-pyrrolidinohexiophenone,itsoptical,positional,andgeometric
409isomers,salts,andsaltsofisomers(Othernames:MPHP;4'-methyl-alpha-
410pyrrolidinohexanophenone;1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one);
411 (zz)alpha-pyrrolidinoheptaphenone,itsoptical,positional,andgeometricisomers,
412salts,andsaltsofisomers(Othernames:PV8;1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one);
413 (aaa)4'-chloro-alpha-pyrrolidinovalerophenone,itsoptical,positional,andgeometric
414isomers,salts,andsaltsofisomers(Othernames:4-chloro-α-PVP; 4'-chloro-alpha-
415pyrrolidinopentiophenone;1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one);
416 (9)Khat,toincludeallpartsoftheplantpresentlyclassifiedbotanicallyascatha
417edulis,whethergrowingornot;theseedsthereof;anyextractfromanypartofsuchplant;and
418everycompound,manufacture,salt,derivative,mixture,orpreparationoftheplant,itsseedor
419extracts.
HB1367 12 420 3.ThedepartmentofhealthandseniorservicesshallplaceasubstanceinScheduleII
421ifitfindsthat:
422 (1)Thesubstancehashighpotentialforabuse;
423 (2)ThesubstancehascurrentlyacceptedmedicaluseintreatmentintheUnited
424States,orcurrentlyacceptedmedicalusewithsevererestrictions;and
425 (3)Theabuseofthesubstancemayleadtoseverepsychicorphysicaldependence.
426 4.ThecontrolledsubstanceslistedinthissubsectionareincludedinScheduleII:
427 (1)Anyofthefollowingsubstanceswhetherproduceddirectlyorindirectlyby
428extractionfromsubstancesofvegetableorigin,orindependentlybymeansofchemical
429synthesis,orbycombinationofextractionandchemicalsynthesis:
430 (a)Opiumandopiate;andanysalt,compound,derivativeorpreparationofopiumor
431opiate,excludingapomorphine,thebaine-derivedbutorphanol,dextrorphan,nalbuphine,
432nalmefene,naloxegol,naloxone,andnaltrexone,andtheirrespectivesalts,butincludingthe
433following:
434 a.Rawopium;
435 b.Opiumextracts;
436 c.Opiumfluid;
437 d.Powderedopium;
438 e.Granulatedopium;
439 f.Tinctureofopium;
440 g.Codeine;
441 h.Dihydroetorphine;
442 i.Ethylmorphine;
443 j.Etorphinehydrochloride;
444 k.Hydrocodone;
445 l.Hydromorphone;
446 m.Metopon;
447 n.Morphine;
448 o.Oripavine;
449 p.Oxycodone;
450 q.Oxymorphone;
451 r.Thebaine;
452 (b)Anysalt,compound,derivative,orpreparationthereofwhichischemically
453equivalentoridenticalwithanyofthesubstancesreferredtointhissubdivision,butnot
454includingtheisoquinolinealkaloidsofopium;
455 (c)Opiumpoppyandpoppystraw;
HB1367 13 456 (d)Cocaleavesandanysalt,compound,derivative,orpreparationofcocaleaves,and
457anysalt,compound,derivative,orpreparationthereofwhichischemicallyequivalentor
458identicalwithanyofthesesubstances,butnotincludingthefollowing:
459 a.Decocainizedcocaleavesorextractionsofcocaleaves,whichextractionsdonot
460containcocaineorecgonine;or
461 b.Ioflupane;
462 (e)Concentrateofpoppystraw(thecrudeextractofpoppystrawineitherliquid,
463solidorpowderformwhichcontainsthephenanthrenealkaloidsoftheopiumpoppy);
464 (2)Anyofthefollowingopiates,includingtheirisomers,esters,ethers,salts,and
465saltsofisomers,whenevertheexistenceoftheseisomers,esters,ethers,andsaltsispossible
466withinthespecificchemicaldesignation,dextrorphanandlevopropoxypheneexcepted:
467 (a)Alfentanil;
468 (b)Alphaprodine;
469 (c)Anileridine;
470 (d)Bezitramide;
471 (e)Bulkdextropropoxyphene;
472 (f)Carfentanil;
473 (g)Dihydrocodeine;
474 (h)Diphenoxylate;
475 (i)Fentanyl;
476 (j)Isomethadone;
477 (k)Levo-alphacetylmethadol;
478 (l)Levomethorphan;
479 (m)Levorphanol;
480 (n)Metazocine;
481 (o)Methadone;
482 (p)Methadone-Intermediate,4-cyano-2-dimethylamino-4,4-diphenylbutane;
483 (q)Moramide-Intermediate,2-methyl-3-morpholino-1,1-diphenylpropane-
484carboxylicacid;
485 (r)Pethidine(meperidine);
486 (s)Pethidine-Intermediate-A,4-cyano-1-methyl-4-phenylpiperidine;
487 (t)Pethidine-Intermediate-B,ethyl-4-phenylpiperidine-4-carboxylate;
488 (u)Pethidine-Intermediate-C,1-methyl-4-phenylpiperdine-4-carboxylicacid;
489 (v)Phenazocine;
490 (w)Piminodine;
491 (x)Racemethorphan;
492 (y)Racemorphan;
HB1367 14 493 (z)Remifentanil;
494 (aa)Sufentanil;
495 (bb)Tapentadol;
496 (cc)Thiafentanil;
497 (3)Anymaterial,compound,mixture,orpreparationwhichcontainsanyquantityof
498thefollowingsubstanceshavingastimulanteffectonthecentralnervoussystem:
499 (a)Amphetamine,itssalts,opticalisomers,andsaltsofitsopticalisomers;
500 (b)Lisdexamfetamine,itssalts,isomers,andsaltsofitsisomers;
501 (c)Methamphetamine,itssalts,isomers,andsaltsofitsisomers;
502 (d)Phenmetrazineanditssalts;
503 (e)Methylphenidate;
504 (4)Anymaterial,compound,mixture,orpreparationwhichcontainsanyquantityof
505thefollowingsubstanceshavingadepressanteffectonthecentralnervoussystem,including
506itssalts,isomers,andsaltsofisomerswhenevertheexistenceofthosesalts,isomers,andsalts
507ofisomersispossiblewithinthespecificchemicaldesignation:
508 (a)Amobarbital;
509 (b)Glutethimide;
510 (c)Pentobarbital;
511 (d)Phencyclidine;
512 (e)Secobarbital;
513 (5)Hallucinogenicsubstances:
514 (a)Anymaterialorcompoundwhichcontainsanyquantityofnabilone;
515 (b)Dronabinol[(-)-Δ-9-transtetrahydrocannabinol]inanoralsolutioninadrug
516productapprovedformarketingbytheU.S.FoodandDrugAdministration;
517 (6)Anymaterial,compound,mixture,orpreparationwhichcontainsanyquantityof
518thefollowingsubstances:
519 (a)Immediateprecursortoamphetamineandmethamphetamine:Phenylacetone;
520 (b)Immediateprecursorstophencyclidine(PCP):
521 a.1-phenylcyclohexylamine;
522 b.1-piperidinocyclohexanecarbonitrile(PCC);
523 (c)Immediateprecursortofentanyl:4-anilino-N-phenethyl-4-piperidine(ANPP);
524 (7)Anymaterial,compound,mixture,orpreparationwhichcontainsanyquantityof
525thefollowingalkylnitrites:
526 (a)Amylnitrite;
527 (b)Butylnitrite.
528 5.ThedepartmentofhealthandseniorservicesshallplaceasubstanceinScheduleIII
529ifitfindsthat:
HB1367 15 530 (1)Thesubstancehasapotentialforabuselessthanthesubstanceslistedin
531SchedulesIandII;
532 (2)ThesubstancehascurrentlyacceptedmedicaluseintreatmentintheUnited
533States;and
534 (3)Abuseofthesubstancemayleadtomoderateorlowphysicaldependenceorhigh
535psychologicaldependence.
536 6.ThecontrolledsubstanceslistedinthissubsectionareincludedinScheduleIII:
537 (1)Anymaterial,compound,mixture,orpreparationwhichcontainsanyquantityof
538thefollowingsubstanceshavingapotentialforabuseassociatedwithastimulanteffectonthe
539centralnervoussystem:
540 (a)Benzphetamine;
541 (b)Chlorphentermine;
542 (c)Clortermine;
543 (d)Phendimetrazine;
544 (2)Anymaterial,compound,mixtureorpreparationwhichcontainsanyquantityor
545saltofthefollowingsubstancesorsaltshavingadepressanteffectonthecentralnervous
546system:
547 (a)Anymaterial,compound,mixtureorpreparationwhichcontainsanyquantityor
548saltofthefollowingsubstancescombinedwithoneormoreactivemedicinalingredients:
549 a.Amobarbital;
550 b.Secobarbital;
551 c.Pentobarbital;
552 (b)Anysuppositorydosageformcontaininganyquantityorsaltofthefollowing:
553 a.Amobarbital;
554 b.Secobarbital;
555 c.Pentobarbital;
556 (c)Anysubstancewhichcontainsanyquantityofaderivativeofbarbituricacidorits
557salt;
558 (d)Chlorhexadol;
559 (e)Embutramide;
560 (f)Gammahydroxybutyricacidanditssalts,isomers,andsaltsofisomerscontained
561inadrugproductforwhichanapplicationhasbeenapprovedunderSection505ofthefederal
562Food,Drug,andCosmeticAct;
563 (g)Ketamine,itssalts,isomers,andsaltsofisomers;
564 (h)Lysergicacid;
565 (i)Lysergicacidamide;
566 (j)Methyprylon;
HB1367 16 567 (k)Perampanel,anditssalts,isomers,andsaltsofisomers;
568 (l)Sulfondiethylmethane;
569 (m)Sulfonethylmethane;
570 (n)Sulfonmethane;
571 (o)Tiletamineandzolazepamoranysaltthereof;
572 (3)Nalorphine;
573 (4)Anymaterial,compound,mixture,orpreparationcontaininglimitedquantitiesof
574anyofthefollowingnarcoticdrugsortheirsalts:
575 (a)Notmorethan1.8gramsofcodeineperonehundredmillilitersornotmorethan
576ninetymilligramsperdosageunit,withanequalorgreaterquantityofanisoquinoline
577alkaloidofopium;
578 (b)Notmorethan1.8gramsofcodeineperonehundredmillilitersornotmorethan
579ninetymilligramsperdosageunitwithoneormoreactive,nonnarcoticingredientsin
580recognizedtherapeuticamounts;
581 (c)Notmorethan1.8gramsofdihydrocodeineperonehundredmillilitersornot
582morethanninetymilligramsperdosageunit,withoneormoreactive,nonnarcoticingredients
583inrecognizedtherapeuticamounts;
584 (d)Notmorethanthreehundredmilligramsofethylmorphineperonehundred
585millilitersornotmorethanfifteenmilligramsperdosageunit,withoneormoreactive,
586nonnarcoticingredientsinrecognizedtherapeuticamounts;
587 (e)Notmorethanfivehundredmilligramsofopiumperonehundredmillilitersorper
588onehundredgramsornotmorethantwenty-fivemilligramsperdosageunit,withoneormore
589activenonnarcoticingredientsinrecognizedtherapeuticamounts;
590 (f)Notmorethanfiftymilligramsofmorphineperonehundredmillilitersorperone
591hundredgrams,withoneormoreactive,nonnarcoticingredientsinrecognizedtherapeutic
592amounts;
593 (5)Anymaterial,compound,mixture,orpreparationcontaininganyofthefollowing
594narcoticdrugsortheirsalts:Buprenorphine;
595 (6)Anabolicsteroids.Anydrugorhormonalsubstance,chemicallyand
596pharmacologicallyrelatedtotestosterone(otherthanestrogens,progestins,corticosteroids,
597anddehydroepiandrosterone)thatpromotesmusclegrowth,exceptananabolicsteroidwhich
598isexpresslyintendedforadministrationthroughimplantstocattleorothernonhumanspecies
599andwhichhasbeenapprovedbytheSecretaryofHealthandHumanServicesforthat
600administration.Ifanypersonprescribes,dispenses,ordistributessuchsteroidforhumanuse,
601suchpersonshallbeconsideredtohaveprescribed,dispensed,ordistributedananabolic
602steroidwithinthemeaningofthissubdivision.Unlessspecificallyexceptedorunlesslisted
HB1367 17 603inanotherschedule,anymaterial,compound,mixtureorpreparationcontaininganyquantity
604ofthefollowingsubstances,includingitssalts,estersandethers:
605 (a)3ß,17ß-dihydroxy-5α-androstane;
606 (b)3α,17β-dihydroxy-5α-androstane;
607 (c)5α-androstan-3,17-dione;
608 (d)1-androstenediol(3β,17β-dihydroxy-5α-androst-1-ene);
609 (e)1-androstenediol(3α,17β-dihydroxy-5α-androst-1-ene);
610 (f)4-androstenediol(3β,17β-dihydroxy-androst-4-ene);
611 (g)5-androstenediol(3β,17β-dihydroxy-androst-5-ene);
612 (h)1-androstenedione([5α]-androst-1-en-3,17-dione);
613 (i)4-androstenedione(androst-4-en-3,17-dione);
614 (j)5-androstenedione(androst-5-en-3,17-dione);
615 (k)Bolasterone(7α,17α-dimethyl-17β-hydroxyandrost-4-en-3-one);
616 (l)Boldenone(17β-hydroxyandrost-1,4,-diene-3-one);
617 (m)Boldione;
618 (n)Calusterone(7β,17α-dimethyl-17β-hydroxyandrost-4-en-3-one);
619 (o)Clostebol(4-chloro-17β-hydroxyandrost-4-en-3-one);
620 (p)Dehydrochloromethyltestosterone(4-chloro-17β-hydroxy-17α-methyl-androst-
6211,4-dien-3-one);
622 (q)Desoxymethyltestosterone;
623 (r)4-dihydrotestosterone(17ß-hydroxy-androstan-3-one);
624 (s)Drostanolone(17ß-hydroxy-2α-methyl-5α-androstan-3-one);
625 (t)Ethylestrenol(17α-ethyl-17ß-hydroxyestr-4-ene);
626 (u)Fluoxymesterone(9-fluoro-17α-methyl-1 1ß,17ß-dihydroxyandrost-4-en-3-one);
627 (v)Formebolone(2-formyl-17α-methyl-1 1α,17ß-dihydroxyandrost-1,4-dien-3-one);
628 (w)Furazabol(17α-methyl-17ß-hydroxyandrostano[2,3-c]-furazan);
629 (x)13ß-ethyl-17ß-hydroxygon-4-en-3-one;
630 (y)4-hydroxytestosterone(4,17ß-dihydroxy-androst-4-en-3-one);
631 (z)4-hydroxy-19-nortestosterone(4,17ß-dihydroxy-estr-4-en-3-one);
632 (aa)Mestanolone(17α-methyl-17ß-hydroxy-5α-androstan-3-one);
633 (bb)Mesterolone(1α-methyl-17ß-hydroxy-[5α]-androstan-3-one);
634 (cc)Methandienone(17α-methyl-17ß-hydroxyandrost-1,4-dien-3-one);
635 (dd)Methandriol(17α-methyl-3ß,17ß-dihydroxyandrost-5-ene);
636 (ee)Methasterone(2α,17α-dimethyl-5α-androstan-17β-ol-3-one);
637 (ff)Methenolone(1-methyl-17ß-hydroxy-5α-androst-1-en-3-one);
638 (gg)17α-methyl-3β,17β-dihydroxy-5α-androstane;
639 (hh)17α-methyl-3α,17β-dihydroxy-5α-androstane;
HB1367 18 640 (ii)17α-methyl-3β,17β-dihydroxyandrost-4-ene;
641 (jj)17α-methyl-4-hydroxynandrolone(17α-methyl-4-hydroxy-17β-hydroxyestr -4-en-
6423-one);
643 (kk)Methyldienolone(17α-methyl-17β-hydroxyestra-4,9(10)-dien-3-one);
644 (ll)Methyltrienolone(17α-methyl-17β-hydroxyestra-4,9,1 1-trien-3-one);
645 (mm)Methyltestosterone(17α-methyl-17β-hydroxyandrost-4-en-3-one);
646 (nn)Mibolerone(7α,17α-dimethyl-17β-hydroxyestr-4- en-3-one);
647 (oo)17α-methyl-Δ1-dihydrotestosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-
6483-one)(a.k.a.'17-α-methyl-1-testosterone');
649 (pp)Nandrolone(17β-hydroxyestr-4-ene-3-one);
650 (qq)19-nor-4-androstenediol(3β,17β-dihydroxyestr-4-ene);
651 (rr)19-nor-4-androstenediol(3α,17β-dihydroxyestr -4-ene);
652 (ss)19-nor-4,9(10)-androstadienedione(estra-4,9(10)-diene-3,17-dione);
653 (tt)19-nor-5-androstenediol(3β,17β-dihydroxyestr-5-ene);
654 (uu)19-nor-5-androstenediol(3α,17β-dihydroxyestr -5-ene);
655 (vv)19-nor-4-androstenedione(estr-4-en-3,17-dione);
656 (ww)19-nor-5-androstenedione(estr-5-en-3,17-dione);
657 (xx)Norbolethone(13β,17α-diethyl-17β-hydroxygon-4-en-3-one);
658 (yy)Norclostebol(4-chloro-17β-hydroxyestr -4-en-3-one);
659 (zz)Norethandrolone(17α-ethyl-17β-hydroxyestr -4-en-3-one);
660 (aaa)Normethandrolone(17α-methyl-17β-hydroxyestr -4-en-3-one);
661 (bbb)Oxandrolone(17α-methyl-17β-hydroxy-2-oxa-[5α]-androstan-3-one);
662 (ccc)Oxymesterone(17α-methyl-4,17β-dihydroxyandrost-4-en-3-one);
663 (ddd)metholone(17α-methyl-2-hydroxymethylene-17β-hydroxy-[5α]-androstan-3-
664one);
665 (eee)Prostanozol(17β-hydroxy-5α-androstano[3,2-c]pyrazole);
666 (fff)Stanolone(Δ1-dihydrotestosterone(a.k.a.1-testosterone)(17β-hydroxy-5α-
667androst-1-en-3-one));
668 (ggg)Stanozolol(17α-methyl-17ß-hydroxy-[5α]-androst-2-eno[3,2-c]-pyrazole);
669 (hhh)Stenbolone(17ß-hydroxy-2-methyl-[5α]-androst-1-en-3-one);
670 (iii)Testolactone(13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oicacid
671lactone);
672 (jjj)Testosterone(17ß-hydroxyandrost-4-en-3-one);
673 (kkk)Tetrahydrogestrinone(13ß,17α-diethyl-17ß-hydroxygon-4,9,11-trien-3-one);
674 (lll)Trenbolone(17ß-hydroxyestr-4,9,11-trien-3-one);
675 (mmm)Anysalt,ester,oretherofadrugorsubstancedescribedorlistedinthis
676subdivision,exceptananabolicsteroidwhichisexpresslyintendedforadministrationthrough
HB1367 19 677implantstocattleorothernonhumanspeciesandwhichhasbeenapprovedbytheSecretary
678ofHealthandHumanServicesforthatadministration;
679 (7)Dronabinol(synthetic)insesameoilandencapsulatedinasoftgelatincapsuleina
680UnitedStatesFoodandDrugAdministrationapproveddrugproduct;
681 (8)Thedepartmentofhealthandseniorservicesmayexceptbyruleanycompound,
682mixture,orpreparationcontaininganystimulantordepressantsubstancelistedin
683subdivisions(1)and(2)ofthissubsectionfromtheapplicationofalloranypartof
684sections195.010to195.320ifthecompound,mixture,orpreparationcontainsoneormore
685activemedicinalingredientsnothavingastimulantordepressanteffectonthecentralnervous
686system,andiftheadmixturesareincludedthereinincombinations,quantity,proportion,or
687concentrationthatvitiatethepotentialforabuseofthesubstanceswhichhaveastimulantor
688depressanteffectonthecentralnervoussystem.
689 7.ThedepartmentofhealthandseniorservicesshallplaceasubstanceinSchedule
690IVifitfindsthat:
691 (1)ThesubstancehasalowpotentialforabuserelativetosubstancesinScheduleIII;
692 (2)ThesubstancehascurrentlyacceptedmedicaluseintreatmentintheUnited
693States;and
694 (3)Abuseofthesubstancemayleadtolimitedphysicaldependenceorpsychological
695dependencerelativetothesubstancesinScheduleIII.
696 8.ThecontrolledsubstanceslistedinthissubsectionareincludedinScheduleIV:
697 (1)Anymaterial,compound,mixture,orpreparationcontaininganyofthefollowing
698narcoticdrugsortheirsaltscalculatedasthefreeanhydrousbaseoralkaloid,inlimited
699quantitiesassetforthbelow:
700 (a)Notmorethanonemilligramofdifenoxinandnotlessthantwenty-five
701microgramsofatropinesulfateperdosageunit;
702 (b)Dextropropoxyphene(alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-
703propionoxybutane);
704 (c)2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol,itssalts,optical
705andgeometricisomers,andsaltsoftheseisomers(includingtramadol);
706 (d)Anyofthefollowinglimitedquantitiesofnarcoticdrugsortheirsalts,whichshall
707includeoneormorenonnarcoticactivemedicinalingredientsinsufficientproportionto
708conferuponthecompound,mixtureorpreparationvaluablemedicinalqualitiesotherthan
709thosepossessedbythenarcoticdrugalone:
710 a.Notmorethantwohundredmilligramsofcodeineperonehundredmillilitersor
711peronehundredgrams;
712 b.Notmorethanonehundredmilligramsofdihydrocodeineperonehundred
713millilitersorperonehundredgrams;
HB1367 20 714 c.Notmorethanonehundredmilligramsofethylmorphineperonehundred
715millilitersorperonehundredgrams;
716 (2)Anymaterial,compound,mixtureorpreparationcontaininganyquantityofthe
717followingsubstances,includingtheirsalts,isomers,andsaltsofisomerswheneverthe
718existenceofthosesalts,isomers,andsaltsofisomersispossiblewithinthespecificchemical
719designation:
720 (a)Alfaxalone;
721 (b)Alprazolam;
722 (c)Barbital;
723 (d)Bromazepam;
724 (e)Camazepam;
725 (f)Carisoprodol;
726 (g)Chloralbetaine;
727 (h)Chloralhydrate;
728 (i)Chlordiazepoxide;
729 (j)Clobazam;
730 (k)Clonazepam;
731 (l)Clorazepate;
732 (m)Clotiazepam;
733 (n)Cloxazolam;
734 (o)Delorazepam;
735 (p)Diazepam;
736 (q)Dichloralphenazone;
737 (r)Estazolam;
738 (s)Ethchlorvynol;
739 (t)Ethinamate;
740 (u)Ethylloflazepate;
741 (v)Fludiazepam;
742 (w)Flunitrazepam;
743 (x)Flurazepam;
744 (y)Fospropofol;
745 (z)Halazepam;
746 (aa)Haloxazolam;
747 (bb)Ketazolam;
748 (cc)Loprazolam;
749 (dd)Lorazepam;
750 (ee)Lormetazepam;
HB1367 21 751 (ff)Mebutamate;
752 (gg)Medazepam;
753 (hh)Meprobamate;
754 (ii)Methohexital;
755 (jj)Methylphenobarbital(mephobarbital);
756 (kk)Midazolam;
757 (ll)Mifepristone;
758 (mm)Nimetazepam;
759 [(mm)] (nn)Nitrazepam;
760 [(nn)] (oo)Nordiazepam;
761 [(oo)] (pp)Oxazepam;
762 [(pp)] (qq)Oxazolam;
763 [(qq)] (rr)Paraldehyde;
764 [(rr)](ss)Petrichloral;
765 [(ss)](tt)Phenobarbital;
766 [(tt)](uu)Pinazepam;
767 [(uu)] (vv)Prazepam;
768 [(vv)] (ww)Quazepam;
769 [(ww)] (xx)Suvorexant;
770 [(xx)] (yy)Temazepam;
771 [(yy)] (zz)Tetrazepam;
772 [(zz)] (aaa)Triazolam;
773 [(aaa)] (bbb)Zaleplon;
774 [(bbb)] (ccc)Zolpidem;
775 [(ccc)] (ddd)Zopiclone;
776 (3)Anymaterial,compound,mixture,orpreparationwhichcontainsanyquantityof
777thefollowingsubstanceincludingitssalts,isomersandsaltsofisomerswheneverthe
778existenceofsuchsalts,isomersandsaltsofisomersispossible:fenfluramine;
779 (4)Anymaterial,compound,mixture,orpreparationwhichcontainsanyquantityof
780thefollowingsubstances,includingitssalts,isomers,andsaltsofisomers,wheneverthe
781existenceofsuchsalts,isomers,andsaltsofisomersispossible:Lorcaserin;
782 (5)Anymaterial,compound,mixtureorpreparationcontaininganyquantityofthe
783followingsubstanceshavingastimulanteffectonthecentralnervoussystem,includingtheir
784salts,isomersandsaltsofisomers:
785 (a)Cathine((+)-norpseudoephedrine);
786 (b)Diethylpropion;
787 (c)Fencamfamin;
HB1367 22 788 (d)Fenproporex;
789 (e)Mazindol;
790 (f)Mefenorex;
791 (g)Modafinil;
792 (h)Pemoline,includingorganometalliccomplexesandchelatesthereof;
793 (i)Phentermine;
794 (j)Pipradrol;
795 (k)Sibutramine;
796 (l)SPA((-)-1-dimethyamino-1,2-diphenylethane);
797 (6)Anymaterial,compound,mixtureorpreparationcontaininganyquantityofthe
798followingsubstance,includingitssalts:
799 (a)Butorphanol(includingitsopticalisomers);
800 (b)Eluxadoline(5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-
801oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic
802acid)(includingitsopticalisomers)anditssalts,isomers,andsaltsofisomers;
803 (c)Pentazocine;
804 (7)Ephedrine,itssalts,opticalisomersandsaltsofopticalisomers,whenthe
805substanceistheonlyactivemedicinalingredient;
806 (8)Thedepartmentofhealthandseniorservicesmayexceptbyruleanycompound,
807mixture,orpreparationcontaininganydepressantsubstancelistedinsubdivision(1)ofthis
808subsectionfromtheapplicationofalloranypartofsections195.010to195.320andsections
809579.015to579.086ifthecompound,mixture,orpreparationcontainsoneormoreactive
810medicinalingredientsnothavingadepressanteffectonthecentralnervoussystem,andifthe
811admixturesareincludedthereinincombinations,quantity,proportion,orconcentrationthat
812vitiatethepotentialforabuseofthesubstanceswhichhaveadepressanteffectonthecentral
813nervoussystem.
814 9.ThedepartmentofhealthandseniorservicesshallplaceasubstanceinScheduleV
815ifitfindsthat:
816 (1)Thesubstancehaslowpotentialforabuserelativetothecontrolledsubstances
817listedinScheduleIV;
818 (2)ThesubstancehascurrentlyacceptedmedicaluseintreatmentintheUnited
819States;and
820 (3)Thesubstancehaslimitedphysicaldependenceorpsychologicaldependence
821liabilityrelativetothecontrolledsubstanceslistedinScheduleIV.
822 10.ThecontrolledsubstanceslistedinthissubsectionareincludedinScheduleV:
823 (1)Anycompound,mixtureorpreparationcontaininganyofthefollowingnarcotic
824drugsortheirsaltscalculatedasthefreeanhydrousbaseoralkaloid,inlimitedquantitiesas
HB1367 23 825setforthbelow,whichalsocontainsoneormorenonnarcoticactivemedicinalingredientsin
826sufficientproportiontoconferuponthecompound,mixtureorpreparationvaluablemedicinal
827qualitiesotherthanthosepossessedbythenarcoticdrugalone:
828 (a)Notmorethantwoandfive-tenthsmilligramsofdiphenoxylateandnotlessthan
829twenty-fivemicrogramsofatropinesulfateperdosageunit;
830 (b)Notmorethanonehundredmilligramsofopiumperonehundredmillilitersorper
831onehundredgrams;
832 (c)Notmorethanfive-tenthsmilligramofdifenoxinandnotlessthantwenty-five
833microgramsofatropinesulfateperdosageunit;
834 (2)Anymaterial,compound,mixtureorpreparationwhichcontainsanyquantityof
835thefollowingsubstancehavingastimulanteffectonthecentralnervoussystemincludingits
836salts,isomersandsaltsofisomers:pyrovalerone;
837 (3)Anycompound,mixture,orpreparationcontaininganydetectablequantityof
838pseudoephedrineoritssaltsoropticalisomers,orsaltsofopticalisomersoranycompound,
839mixture,orpreparationcontaininganydetectablequantityofephedrineoritssaltsoroptical
840isomers,orsaltsofopticalisomers;
841 (4)Unlessspecificallyexemptedorexcludedorunlesslistedinanotherschedule,any
842material,compound,mixture,orpreparationwhichcontainsanyquantityofthefollowing
843substanceshavingadepressanteffectonthecentralnervoussystem,includingitssalts:
844 (a)Brivaracetam((25)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide)(also
845referredtoasBRV;UCB-34714;Briviact);
846 (b)Ezogabine[N-[2-amino-4(4-fluorobenzylamino)-phenyl]-carbamicacidethyl
847ester];
848 (c)Lacosamide[(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide];
849 (d)Pregabalin[(S)-3-(aminomethyl)-5-methylhexanoicacid];
850 (5)Anydrugproductinfinisheddosageformulationthathasbeenapprovedbythe
851U.S.FoodandDrugAdministrationthatcontainscannabidiol(2-[1R-3-methyl-6R-(1-
852methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol)derivedfromcannabisandno
853morethan0.1percent(w/w)residualtetrahydrocannabinols.
854 11.Ifanycompound,mixture,orpreparationasspecifiedinsubdivision(3)of
855subsection10ofthissectionisdispensed,sold,ordistributedinapharmacywithouta
856prescription:
857 (1)Allpackagesofanycompound,mixture,orpreparationcontaininganydetectable
858quantityofpseudoephedrine,itssaltsoropticalisomers,orsaltsofopticalisomersor
859ephedrine,itssaltsoropticalisomers,orsaltsofopticalisomers,shallbeofferedforsaleonly
860frombehindapharmacycounterwherethepublicisnotpermitted,andonlybyaregistered
861pharmacistorregisteredpharmacytechnician;and
HB1367 24 862 (2)Anypersonpurchasing,receivingorotherwiseacquiringanycompound,mixture,
863orpreparationcontaininganydetectablequantityofpseudoephedrine,itssaltsoroptical
864isomers,orsaltsofopticalisomersorephedrine,itssaltsoropticalisomers,orsaltsofoptical
865isomersshallbeatleasteighteenyearsofage;and
866 (3)Thepharmacist,internpharmacist,orregisteredpharmacytechnicianshallrequire
867anyperson,priortosuchperson'spurchasing,receivingorotherwiseacquiringsuch
868compound,mixture,orpreparationtofurnishsuitablephotoidentificationthatisissuedbya
869stateorthefederalgovernmentoradocumentthat,withrespecttoidentification,is
870consideredacceptableandshowingthedateofbirthoftheperson;
871 (4)Thesellershalldelivertheproductdirectlyintothecustodyofthepurchaser.
872 12.Pharmacists,internpharmacists,andregisteredpharmacytechniciansshall
873implementandmaintainanelectroniclogofeachtransaction.Suchlogshallincludethe
874followinginformation:
875 (1)Thename,address,andsignatureofthepurchaser;
876 (2)Theamountofthecompound,mixture,orpreparationpurchased;
877 (3)Thedateandtimeofeachpurchase;and
878 (4)Thenameorinitialsofthepharmacist,internpharmacist,orregisteredpharmacy
879technicianwhodispensedthecompound,mixture,orpreparationtothepurchaser.
880 13.Eachpharmacyshallsubmitinformationregardingsalesofanycompound,
881mixture,orpreparationasspecifiedinsubdivision(3)ofsubsection10ofthissectionin
882accordancewithtransmissionmethodsandfrequencyestablishedbythedepartmentby
883regulation;
884 14.Nopersonshalldispense,sell,purchase,receive,orotherwiseacquirequantities
885greaterthanthosespecifiedinthischapter.
886 15.Allpersonswhodispenseorofferforsalepseudoephedrineandephedrine
887productsinapharmacyshallensurethatallsuchproductsarelocatedonlybehindapharmacy
888counterwherethepublicisnotpermitted.
889 16.Thepenaltiesforaknowingorrecklessviolationoftheprovisionsofsubsections
89011to15ofthissectionarefoundinsection579.060.
891 17.Theschedulingofsubstancesspecifiedinsubdivision(3)ofsubsection10ofthis
892sectionandsubsections11,12,14,and15ofthissectionshallnotapplytoanycompounds,
893mixtures,orpreparationsthatareinliquidorliquid-filledgelcapsuleformortoany
894compound,mixture,orpreparationspecifiedinsubdivision(3)ofsubsection10ofthis
895sectionwhichmustbedispensed,sold,ordistributedinapharmacypursuanttoa
896prescription.
897 18.Themanufacturerofadrugproductoranotherinterestedpartymayapplywith
898thedepartmentofhealthandseniorservicesforanexemptionfromthissection.The
HB1367 25 899departmentofhealthandseniorservicesmaygrantanexemptionbyrulefromthissectionif
900thedepartmentfindsthedrugproductisnotusedintheillegalmanufactureof
901methamphetamineorothercontrolledordangeroussubstances.Thedepartmentofhealth
902andseniorservicesshallrelyonreportsfromlawenforcementandlawenforcement
903evidentiarylaboratoriesindeterminingiftheproposedproductcanbeusedtomanufacture
904illicitcontrolledsubstances.
905 19.Thedepartmentofhealthandseniorservicesshallreviseandrepublishthe
906schedulesannually.
907 20.Thedepartmentofhealthandseniorservicesshallpromulgaterulesunderchapter
908536regardingthesecurityandstorageofScheduleVcontrolledsubstances,asdescribedin
909subdivision(3)ofsubsection10ofthissection,fordistributorsasregisteredbythe
910departmentofhealthandseniorservices.
911 21.Logsoftransactionsrequiredtobekeptandmaintainedbythissectionand
912section195.417shallcreatearebuttablepresumptionthatthepersonwhosenameappearsin
913thelogsisthepersonwhosetransactionsarerecordedinthelogs.
579.018.1.Apersoncommitstheoffenseofcoercedcriminalabortionbymeans
2offraudifthepersonknowinglyandintentionallyengagesintheuseofanabortion-
3inducingdrugonapregnantwomanwithoutherknowledgeorconsentwiththeintent
4tocauseanabortion.
5 2.TheoffenseofcoercedcriminalabortionbymeansoffraudisaclassBfelony.
6 3.Aprosecutionofapersonunderthissectionshallnotbeadefenseagainsta
7prosecutionunderanyotherprovisionoflaw,includingmurder,ifthepersoncommits
8theoffenseofcoercedcriminalabortionbymeansoffraudandtheuseofanabortion-
9inducingdrugresultsinthedeathorseriousbodilyinjuryofthepregnantwoman.
✔
HB1367 26